| Progress in clinical trial of histone deacetylase （HDAC） inhibitors for non-small cell lung cancers |
| |
| 作者姓名： | Xingsheng Hu Lin Wang Lin Lin Yuankai Shi |
| |
| 作者单位： | Beiiing Key Laboratory of Clinical Research on Molecular-targeted Antimmor Agents, Department of MedicalOncology, Cancer Institute ＆ Hospital, Chinese Academy of Medical Sciences ＆ Peking Union Medical college（CAMS ＆ PUMC）, Beiiing 10021, China |
| |
| 基金项目： | Supported by a grant of New Key Drug Formulation Grand in the 12th Five-Year Plan of the National Science and Technology Project of China （No. 2012zx09303-012）. |
| |
| 摘 要： | Histone deacetylase （HDAC） inhibitors, which represent a structurally diverse group of molecules, have emerged as a novel therapeutic class of molecules with significant anticancer potential. Vorinostat and romidepsin, known as the first generation of HDAC inhibitors, were approved in the United States for the treatment of T-cell lymphomas. Preliminary activity of HDAC inhibitors has also been observed in non-small cell lung cancer （NSCLC） in combination with the existing treatment regimens, of which is the focus of the current review.
|
| 关 键 词： | 组蛋白去乙酰化酶 非小细胞肺癌 HDAC 抑制剂 临床试验 脱乙酰 治疗方案 第一代 |
Progress in clinical trial of histone deacetylase （HDAC） inhibitors for non-small cell lung cancers |
| |
| Authors: | 《 |
| |
| Abstract: | histone deacetylase （HDAC） inhibitor non-small cell lung cancer （NSCLC） treatment progress |
| |
| Keywords: | histone deacetylase （HDAC） inhibitor non-small cell lung cancer （NSCLC） treatment progress |
| 本文献已被 维普 等数据库收录！ |
